Lonopin 40mg Injection contains Enoxaparin sodium, a low molecular weight heparin (LMWH) used as an anticoagulant for the prevention and treatment of thromboembolic disorders. Enoxaparin acts by inhibiting factor Xa and IIa (thrombin), thereby reducing the formation of fibrin clots. Lonopin 40mg Injection is indicated for the prophylaxis of deep vein thrombosis (DVT) in patients undergoing orthopedic or abdominal surgery, as well as for the treatment of acute coronary syndromes, including unstable angina and non-Q-wave myocardial infarction. It is also utilized in the management of established venous thromboembolism (VTE), including deep vein thrombosis and pulmonary embolism. The injection is administered subcutaneously, with dosing individualized based on patient weight, renal function, and clinical condition. Monitoring of anti-factor Xa activity may be necessary in special populations such as those with renal impairment, obesity, or pregnancy. Common adverse effects include bleeding, thrombocytopenia, and injection site reactions. Caution is advised in patients with active bleeding, hemorrhagic disorders, or hypersensitivity to enoxaparin or heparin. Lonopin 40mg Injection should be used under strict medical supervision, adhering to recommended guidelines to optimize therapeutic efficacy and minimize risks.